We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type |
---|---|---|---|
Merrimack Pharmaceuticals Inc | NASDAQ:MACK | NASDAQ | Common Stock |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
-0.03 | -0.20% | 15.00 | 14.95 | 19.44 | 15.03 | 14.995 | 15.02 | 187,592 | 05:00:01 |
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Amendment No. 2 to
SCHEDULE TO
(Rule 14d-100)
TENDER OFFER STATEMENT UNDER SECTION 14(d)(1) OR 13(e)(1)
OF THE SECURITIES EXCHANGE ACT OF 1934
M ERRIMACK P HARMACEUTICALS , I NC .
(Name of Subject Company (Issuer) and Filing Person (Offeror))
4.50% Convertible Senior Notes due 2020
(Title of Class of Securities)
590328AA8
(CUSIP Number of Class of Securities)
Richard Peters, M.D., Ph.D.
Merrimack Pharmaceuticals, Inc.
One Kendall Square, Suite B7201
Cambridge, Massachusetts, 02139
(617) 441-1000
(Name, address, and telephone number of person authorized to receive notices and communications on behalf of filing persons)
Copies to:
Michael J. Zeidel, Esq.
Skadden, Arps, Slate, Meagher & Flom LLP
Four Times Square
New York, New York 10036
(212) 735-3000
CALCULATION OF FILING FEE
Transaction Valuation (1) | Amount of Filing Fee (2) | |
$22,527,900 | $2,804.72 |
(1) | Calculated solely for purposes of determining the amount of the filing fee. The calculation of the Transaction Valuation assumes that all $25,031,000 aggregate principal amount of the Companys 4.50% Convertible Senior Notes due 2020 are purchased at the tender offer price of $900.00 per $1,000 principal amount of such notes. |
(2) | The amount of the filing fee, calculated in accordance with Rule 0-11 of the Securities Exchange Act of 1934, as amended, and the Fee Rate Advisory #1 for Fiscal Year 2018, equals $124.50 for each $1,000,000 of the value of the transaction. |
☒ | Check the box if any part of the fee is offset as provided by Rule 0-11(a)(2) and identify the filing with which the offsetting fee was previously paid. Identify the previous filing by registration statement number, or the Form or Schedule and the date of its filing. |
Amount Previously Paid: $2,804.72 | Filing Party: Merrimack Pharmaceuticals, Inc. | |
Form or Registration No.: SC TO-I | Date Filed: October 13, 2017 |
☐ | Check the box if the filing relates solely to preliminary communications made before the commencement of a tender offer. |
Check the appropriate boxes below to designate any transactions to which the statement relates:
☐ | third party tender offer subject to Rule 14d-1. |
☒ | issuer tender offer subject to Rule 13e-4. |
☐ | going private transaction subject to Rule 13e-3. |
☐ | amendment to Schedule 13D under Rule 13d-2. |
Check the following box if the filing is a final amendment reporting the results of the tender offer: ☐
This Amendment No. 2 (Amendment No. 2) amends and supplements the Tender Offer Statement on Schedule TO (the Schedule TO) originally filed with the United States Securities and Exchange Commission (the SEC) on October 13, 2017, as previously amended by Amendment No. 1 (Amendment No. 1) on October 27, 2017, by Merrimack Pharmaceuticals, Inc. (the Company) in connection with its offer to purchase (the Tender Offer), upon the terms and subject to the conditions set forth in the Offer to Purchase dated October 13, 2017 (as it may be amended or supplemented from time to time, the Offer to Purchase) and the related Letter of Transmittal (as it may be amended or supplemented from time to time, the Letter of Transmittal), any and all of the outstanding $25,031,000 aggregate principal amount of its 4.50% Convertible Senior Notes due 2020 (the Notes) for cash in an amount equal to $900.00 per $1,000 principal amount of Notes purchased (exclusive of accrued and unpaid interest).
This Amendment No. 2 is being filed to incorporate by reference the Companys Quarterly Report on Form 10-Q for the quarter ended September 30, 2017 (the Form 10-Q). You should carefully consider the Companys results of operations for its quarter ended September 30, 2017 and the other information contained in the Form 10-Q in connection with deciding whether to tender your Notes in the Tender Offer.
All information in the Offer to Purchase and the related Letter of Transmittal, which were previously filed as Exhibits (a)(1)(A) and (a)(1) (B), respectively, to the Schedule TO, as amended by Amendment No. 1, is hereby expressly incorporated by reference in this Amendment No. 2 in response to all applicable items required in the Schedule TO, except that such information is hereby amended and supplemented to the extent specifically provided herein. Capitalized terms used and not otherwise defined in this Amendment No. 2 shall have the meanings assigned to such terms in the Offer to Purchase as amended or supplemented. You should read this Amendment No. 2 together with the Schedule TO, Amendment No. 1, the Offer to Purchase and the related Letter of Transmittal.
Item 11.
The Offer to Purchase and the Items of the Schedule TO, to the extent such Items incorporate the information contained in the Offer to Purchase, are hereby amended and supplemented as follows:
The section of the Offer to Purchase entitled Additional Information under the subheading Incorporation by Reference is amended and supplemented by deleting the second bullet point in its entirety and inserting in lieu thereof the following language: Our Quarterly Reports on Form 10-Q for the quarterly periods ended March 31, 2017, June 30, 2017 and September 30, 2017, filed on May 10, 2017, August 9, 2017 and November 8, 2017, respectively; and.
2
SIGNATURE
After due inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.
MERRIMACK PHARMACEUTICALS, INC. | ||||
By: | /s/ Richard Peters, M.D., Ph.D. | |||
Name: | Richard Peters, M.D., Ph.D. | |||
Title: |
President, Chief Executive Officer and Director |
Dated: November 8, 2017
3
EXHIBIT INDEX
* Previously filed.
4
1 Year Merrimack Pharmaceuticals Chart |
1 Month Merrimack Pharmaceuticals Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions